Dietz, Julia und Spengler, Ulrich und Müllhaupt, Beat und Schulze Zur Wiesch, Julian und Piecha, Felix und Mauss, Stefan und Seegers, Barbara und Hinrichsen, Holger und Antoni, Christoph und Wietzke-Braun, Perdita und Peiffer, Kai-Henrik und Berger, Annemarie und Matschenz, Katrin und Buggisch, Peter und Backhus, Johanna und Zizer, Eugen und Boettler, Tobias und Neumann-Haefelin, Christoph und Semela, David und Stauber, Rudolf und Berg, Thomas und Berg, Christoph und Zeuzem, Stefan und Vermehren, Johannes und Sarrazin, Christoph
(2021)
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 19 (1).
195-198.e2.
ISSN 1542-7714
Für diesen Eintrag wurde kein Volltext-Dokument angefügt.
Kurzfassung
Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.
1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.
4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.
8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.
Aktionen (Anmeldung erforderlich)
- Eintrag anzeigen
Tools
Tools
